<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical rescue therapies in pediatric glucocorticoid-refractory ulcerative colitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical rescue therapies in pediatric glucocorticoid-refractory ulcerative colitis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medical rescue therapies in pediatric glucocorticoid-refractory ulcerative colitis</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Infliximab</td> <td class="subtitle1_left">Cyclosporine</td> <td class="subtitle1_left">Tacrolimus</td> </tr> <tr> <td><strong>Tests before treatment</strong></td> <td>Excluding tuberculosis; serology for varicella, hepatitis B, and hepatitis C (and HIV when appropriate).</td> <td>CBC, chemistries including creatinine and magnesium, liver tests, EBV titers, spot creatinine clearance.</td> <td>CBC, chemistries including creatinine and magnesium, liver tests, EBV titers, spot creatinine clearance.</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Initial dosing</strong></td> <td>5 to 10 mg/kg for dose 1. Emerging data in ASC indicate that intensified induction is more successful than standard 5 mg/kg given at weeks 0, 2, and 6.</td> <td>2 mg/kg/day continuous intravenous infusion.</td> <td>0.1 mg/kg per dose orally twice daily.</td> </tr> <tr> <td><strong>Main toxicity</strong></td> <td>Infusion reactions, immune suppression, and rare opportunistic infections.</td> <td>Hypertension, hyperglycemia, hypomagnesemia, immune suppression, azotemia, seizures (dose- and hypercholesterolemia-dependent), hirsutism, gingival hyperplasia.</td> <td>As per cyclosporine, but less hirsutism and gingival hyperplasia. Additionally, self-remitting tremor.</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Ongoing treatment following response</strong></td> <td>Continue regularly scheduled maintenance infusions (4 to 8 weeks), ideally guided by therapeutic drug monitoring.</td> <td>Initiate thiopurines (or other agent to maintain remission such as vedolizumab) so that cyclosporine can be discontinued within several months.</td> <td>As per cyclosporine.</td> </tr> <tr> <td><strong>Target drug levels during induction</strong></td> <td>Limited data on target levels during induction.</td> <td>Aim initially for 150 to 300 ng/mL.</td> <td>Aim initially for 10 to 15 ng/mL.</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Target levels once response achieved</strong></td> <td>5 to 10 microgram/mL at trough during maintenance.</td> <td>100 to 200 ng/mL once remission achieved.</td> <td>5 to 7 ng/mL once remission achieved; longer duration treatment using lower levels of 2 to 5 have been reported.</td> </tr> <tr> <td><strong>Monitoring/prevention of toxicity</strong></td> <td>PJP prophylaxis to be considered with IMM and steroids.</td> <td>PJP prophylaxis to be strongly considered with IMM and steroids. Monitor drug levels, creatinine, glucose, electrolytes (including magnesium), lipid levels, blood pressure.</td> <td>PJP prophylaxis to be strongly considered with IMM and steroids. Monitor drug levels, creatinine, glucose, electrolytes (including magnesium), lipid levels, blood pressure.</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>This table outlines the main options for medical therapy of acute severe ulcerative colitis in children that is refractory to treatment with glucocorticoids (ie, no clinically meaningful response to a 7- to 10-day course of intravenous glucocorticoids). Use of sequential therapy (infliximab followed by cyclosporine or tacrolimus, or vice versa) remains controversial and is not recommended.</p>
If the patient with severe or refractory colitis responds to rescue therapy with cyclosporine, tacrolimus, or infliximab, then the glucocorticoids can be gradually tapered and withdrawn. If cyclosporine or tacrolimus was used for induction, the patient should be transitioned to a thiopurine or other long-term maintenance agent within 3 to 4 months.</div><div class="graphic_footnotes"><p>CBC: complete blood count; EBV: Epstein-Barr virus; ASC: acute severe colitis; IMM: immunomodulators; PJP: <em>Pneumocystis jiroveci pneumonia</em>.</p>
<p>* Maintenance therapy can be given every 8 weeks after induction, if clinically indicated.</p>
<p>¶ Neurotoxicity (manifested as paresthesias, tremors, and seizures) is promoted by hypocholesterolemia (&lt;120 mg/dL) and hypomagnesemia (&lt;1.5 mg/dL); if the latter occurs, dose of cyclosporine should be lowered.</p>
<p>Δ Hypertension can be seen in up to 40% of subjects and usually responds to calcium channel blockers (the latter, however, can increase cyclosporine levels).</p>
<p>◊ Serum creatinine &gt;1.4 mg/dL or at least 33% over baseline (usually respond to cyclosporine dose adjustment).</p>
<p>§ Drug interactions should be checked with Lexi-Interact when initiated and for any change in drug therapy.</p>
¥ If oral drug dose has been changed, monitor levels 1 week later.</div><div class="graphic_reference">From: Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:292. DOI: <a href="https://journals.lww.com/jpgn/fulltext/2018/08000/Management_of_Paediatric_Ulcerative_Colitis,_Part.25.aspx" target="_blank">10.1097/MPG.0000000000002036</a>. Copyright © 2018 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Adapted with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 98961 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
